ライフサイエンスコーパス: 11C

1 11C HED retention indexes (RIs), which reflect nerve den

2 11C-(R)-PK11195 positron emission tomography reveals inc

3 11C-(R)-Rolipram binding in the brain was measured using

4 11C-(R)-Rolipram brain positron emission tomography scan

5 11C-dLop may be superior to 11C-loperamide in measuring

6 11C-JHU75528 formed several hydrophilic metabolites, but

7 11C-JHU75528 holds promise as a radiotracer with suitabl

8 11C-JHU75528 readily entered the mouse and baboon brain

9 11C-Loperamide is an avid substrate for P-glycoprotein (

10 11C-MeNTI binding in tumor and healthy lung tissue was s

11 11C-PBR28 PET can detect the 18-kDa translocator protein

12 11C-Pittsburgh compound B and 11C-(R)-PK11195 positron e

13 [11C]-(+)-PHNO binding in SN was related to self-reported

14 [11C]CUMI-101 is the first selective serotonin receptor (

15 [11C]Dihydrotetrabenazine ([11C]DTBZ) binds specifically

16 [11C]DPN VD did not undergo systematic changes between ti

17 [11C]FLB 457 binding potential, specific compared to nond

18 [11C]GV1-57 additionally measured rates of neuron regener

19 [11C]GV1-57 monitored native OSN population dynamics in r

20 [11C]LY2795050 volume of distribution values in amygdala-

21 [11C]LY2795050 volume of distribution values in an amygda

22 [11C]MeDAS-PET is a promising imaging marker for monitori

23 [11C]Phenethylguanidine ([11C]1a) and 12 analogues ([11C]

24 [11C]PIB distribution volume ratios were calculated using

25 [11C]PiB PET could be valuable in imaging amyloid deposit

26 [11C]PiB PET was used to image amyloid deposition in 11 c

27 [11C]PiB shows increased binding following TBI.

28 t dynamic imaging with 18F-FDG (n = 6) and 1-11C-acetate (n = 6).

29 uccessfully extracted for both 18F-FDG and 1-11C-acetate in rats.

30 tions were 0.930 for 18F-FDG and 0.972 for 1-11C-acetate.

31 MBF was estimated in 24 rats at rest using 1-11C-acetate (MBF-Ace) and compared with measurements obt

32 to the SEPT6 and SEPT7 groups (SEPT6C/8C/10C/11C and SEPT7C, respectively) and provide clear evidence

33 omer [d(G 1A 2T 3A 4 G 5 C 6 G 7 C 8T 9A 10T 11C 12)] 2 are studied by using deuterium solid-state NM

34 omer [d(G 1A 2T 3A 4 G 5 C 6 G 7 C 8T 9A 10T 11C 12)] 2 are studied using deuterium solid-state NMR (

35 raphic (PET) imaging study using carbon 11 ([11C])-labeled PBR28 in patients with temporal lobe epile

36 the complete structures of the serotype 11B, 11C, and 11F polysaccharides and a revision to the serot

37 Compound [11C]1c, [11C]-p-hydroxyphenethylguanidine, which has a rapid NET

38 esis and evaluation of 3-[3,5-dimethyl-4-(4-[11C]methylpiperazinecarbonyl)-1H-pyrrol-2-ylmethylene]-2

39 ci in patients with TLE ([11C]PBR28: 2%-6%; [11C]DPA-713: 4%-9%).

40 ved in 10 steps with a total yield of 9.7%, [11C]14 was obtained through radiomethylation in a range

41 All subjects underwent a 11C-PIB scan and structural MRI.

42 injection of 11C-methylaminoisobutyric acid (11C-MeAIB).

43 We acquired [11C]DASB PET images for 26 additional patients with SAD

44 Neuroinflammation did not affect [11C]MeDAS uptake in the brain as long as the myelin shea

45 drug of abuse underwent PET scanning after [11C]-(+)-PHNO.

46 indole (11C-MeNTI) and the mu-opioid agonist 11C-carfentanil (11C-CFN) in patients with lung carcinom

47 The use of alpha [11C] methyl-L-tryptophan positron emission tomography sc

48 Although 11C-PIB accumulation is greater in patients with AD than

49 ent 3 T magnetic resonance imaging, amyloid (11C-PiB) positron emission tomography and tau (18F-AV-14

50 nethylguanidine ([11C]1a) and 12 analogues ([11C]1b-m) were synthesized and evaluated as radiotracers

51 le; has as much alphaGlcNAc as 11F, 11B, and 11C CPS do; and may represent a new serotype.

52 Autopsy and 11C-PiB positron emission tomography.

53 11C-Pittsburgh compound B and 11C-(R)-PK11195 positron emission tomography was used to

54 of the combined 11C-dihydrotetrabenazine and 11C-Pittsburgh compound-B results.

55 to evaluate serotonin terminal function and 11C-raclopride PET to evaluate dopamine release.

56 ng for the assessment of tract integrity and 11C-raclopride positron emission tomography to measure c

57 rrelation between levels of amyloid load and 11C-(R)-PK11195 binding potentials at a voxel level with

58 and suggest the suitability of 11C-MeNTI and 11C-CFN as investigational probes of lung carcinoma biol

59 Paired measurements of 11C-MeNTI and 11C-CFN binding were performed in biopsy-proven small-ce

60 Increased binding of 11C-MeNTI and 11C-CFN was detected in all tumor types studied.

61 -nonspecific binding ratios of 11C-MeNTI and 11C-CFN, respectively.

62 ssed as standardized uptake value ratio, and 11C-PiB were given as distribution volume ratio.

63 AD, including CERAD score, Braak score, and 11C-PiB retention, with serum markers of glucose homeost

64 e cortical distribution maps of 18F-T807 and 11C-PiB.

65 triatal vesicular monoamine transporters and 11C-Pittsburgh compound-B positron emission tomography i

66 torage was performed with [13N]-ammonia and [11C]-epinephrine 4 to 12 weeks later.

67 To test this hypothesis, amphetamine and [11C]FLB 457 positron emission tomography were used to me

68 re of serotonin synthesis rate capacity and [11C]DASB binding potential as an index of serotonin tran

69 tes [123I]-m-iodobenzylguanidine (MIBG) and [11C]-m-hydroxyephedrine (HED) are used as markers of car

70 ipsilateral to contralateral [11C]PBR28 and [11C]DPA-713 standardized uptake values from temporal reg

71 Relative [11C]PBR28 and [11C]DPA-713 uptakes were higher ipsilateral than contral

72 e (dopamine D2/D3 receptor radioligand) and [11C]cocaine (dopamine transporter radioligand).

73 ects using positron emission tomography and [11C]raclopride (dopamine D2 receptor radioligand sensiti

74 ects using positron emission tomography and [11C]raclopride (dopamine D2/D3 receptor radioligand) and

75 tomography imaging with the D2/D3 antagonist 11C-raclopride, we analysed striatal D2/D3 availability

76 ivo of the selective delta-opioid antagonist 11C-methylnaltrindole (11C-MeNTI) and the mu-opioid agon

77 ing in the brain was measured using arterial 11C-(R)-rolipram levels to correct for the influence of

78 Amyloid-positivity was defined as 11C-Pittsburgh compound B target-to-cerebellar ratio abo

79 henyl)-6-hydroxybenzothiazole (also known as 11C-6-OH-BTA-1 or 11C-PIB) binds to amyloid-beta (Abeta)

80 and carbon 11-labeled Pittsburgh Compound B (11C-PiB) positron emission tomographic (PET) imaging.

81 variants using [11C]-Pittsburgh compound B ([11C]PIB) and [18F]-labeled fluorodeoxyglucose positron e

82 n, carbon 11-labeled Pittsburgh Compound B ([11C]PiB) PET imaging to measure amyloid burden, and stru

83 th carbon 11-labeled Pittsburgh Compound B ([11C]PiB) positron emission tomography (PET).

84 Because [11C]raclopride competes with endogenous dopamine for bin

85 laminomethyl-phenylsulfanyl)- benzonitrile ([11C]DASB), a serotonin transporter radioligand.

86 ly, we found an inverse relationship between 11C-PIB BPND and rCBF MR imaging in the voxel-based anal

87 Both 11C-loperamide and its putative radiometabolite 11C-dLop

88 Amyloid load assessed by both 11C-PIB PET and amyloid histology was highest in the fro

89 tidepressant pharmacotherapy completed both [11C]WAY-100635 PET scans with a metabolite-corrected art

90 who had 2 or more OGTTs and underwent brain 11C-PiB positron emission tomography.

91 n resistance were also correlated with brain 11C-PiB retention in an additional 53 living subjects fr

92 conventional clinical evaluation followed by 11C-dihydrotetrabenazine positron emission tomography im

93 variants in four women: missense mutation c.11C --> A (p.A4E) was found in two women; deletion c.

94 raclopride labeled with radioactive carbon (11C) was performed to measure smoking-induced dopamine r

95 ) and the mu-opioid agonist 11C-carfentanil (11C-CFN) in patients with lung carcinoma using PET.

96 PET with [methyl-(11)C]-choline (11C-choline) can be useful for detecting well-differenti

97 ith Lewy bodies on the basis of the combined 11C-dihydrotetrabenazine and 11C-Pittsburgh compound-B r

98 Compound [11C]1c, [11C]-p-hydroxyphenethylguanidine, which has a r

99 s the ratio of ipsilateral to contralateral [11C]PBR28 and [11C]DPA-713 standardized uptake values fr

100 5%), followed by the temporoparietal cortex (11C-PIB BPND: 0.75+/-0.08; amyloid histology: 13.9%+/-0.

101 ts with Lewy body disease with low cortical [11C]PiB retention.

102 evealed that methylphenidate also decreased [11C]raclopride binding in hippocampus and amygdala and t

103 not rule out the possibility that decreased [11C]raclopride binding reflects decreases in receptor le

104 [11C]Dihydrotetrabenazine ([11C]DTBZ) binds specifically to VMAT2 and is a radioliga

105 l)-4-methyl-1,2,4-triaz ine-3,5(2H,4H)dione (11C-MMP), a 5-HT1AR agonist.

106 The distomer, [11C](+)-12a, failed to give a sustained CB1 receptor-spe

107 healthy controls was reflected by elevated [11C]DASB binding potential in the raphe nuclei region, c

108 The goal of this study was to evaluate 11C-JHU75528, an analog of the selective CB1 antagonist

109 We evaluated 11C-loperamide as a PET radiotracer to measure P-gp func

110 baseline PETs using 6-[18F]fluorodopa (FD), [11C]dihydrotetrabenazine (DTBZ), and 2beta-[11 C]carbome

111 Binding potential estimates from thirty-five 11C-PBR28 PET scans from an independent sample of health

112 components with differential affinities for 11C-PBB3 and 18F-AV-1451, and higher availability of bin

113 gressive supranuclear palsy tau deposits for 11C-PBB3 than 18F-AV-1451.

114 etermine the optimal modeling parameters for 11C-MMP under its new name, 11C-CUMI-101, in Papio anubi

115 specific binding ratio across cell types for 11C-MeNTI (4.32 +/- 1.31; mean +/- SEM) was greater than

116 mpound B and 10 healthy control subjects had 11C-(R)-PK11195 positron emission tomography for compari

117 lve age-matched healthy control subjects had 11C-Pittsburgh compound B and 10 healthy control subject

118 ith control subjects, drug users had higher [11C]-(+)-PHNO binding in the D3-rich midbrain substantia

119 s, had asymmetrically increased hippocampal [11C]PBR28 uptake exceeding the 95% confidence interval o

120 istology: 13.9%+/-0.7%) and the hippocampus (11C-PIB BPND: 0.71+/-0.09; amyloid histology: 9.2%+/-0.9

121 However, 11C-PIB BPND and amyloid histology linearly correlated (

122 parametric imaging method (MRTM2) for human [11C]DASB studies.

123 ft striatum as assessed by reduced change in 11C-raclopride binding compared with control subjects.

124 a widespread, approximately 20% reduction in 11C-(R)-rolipram binding (p = .002), which was not cause

125 thylphenidate induced smaller decrements in [11C]raclopride binding in left and right caudate (blunte

126 The difference in [11C]raclopride's specific binding between placebo and me

127 Increases in [11C]PiB distribution volume ratios in patients with TBI

128 Increased [11C]5-HTP influx rate was observed in the amygdala, raph

129 LPS administration significantly increased [11C]PBR28 binding 30-60%, demonstrating microglial activ

130 nts with TBI showed significantly increased [11C]PiB distribution volume ratios in cortical gray matt

131 We injected 11C-Pittsburgh compound B (PIB) intravenously in transge

132 radiolabeled with positron emitting isotopes 11C and 18F as potential radioligands for positron emiss

133 ty, and favorable plasma and brain kinetics, 11C-CUMI-101 is an excellent candidate for imaging high-

134 Binary classification of carbon 11-labeled [11C]PMP acetylcholinesterase and caudate nucleus [11C]DT

135 e positron emission tomography (PET) ligand [11C](R)PK11195 (PK).

136 ers, using PET and the D3-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin ([11C]-(+)-PHNO

137 y metabolized to 11C-N-desmethyl-loperamide (11C-dLop), which is also a substrate for P-gp and thereb

138 Path analysis revealed that lower [11C]LY2795050 volume of distribution values in this circ

139 The mean 11C HED RI was 0.086 mL of blood per minute per millilit

140 ission tomography (PET) radioligand N-methyl-11C-2-(4-methylaminophenyl)-6-hydroxybenzothiazole (also

141 idinyl)ethynyl]-2-cyclohexen-1-one-O-(methyl-11C)oxime, a negative allosteric modulator of the metabo

142 ynthesis and initial evaluation of [O-methyl-11C]2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-met

143 e [11C]-PIB (Pittsburgh Compound B, N-methyl[11C]2-(4'-methylaminophenyl-6-hydroxybenzathiazole) is u

144 lta-opioid antagonist 11C-methylnaltrindole (11C-MeNTI) and the mu-opioid agonist 11C-carfentanil (11

145 st in the frontal cortex of transgenic mice (11C-PIB BPND: 0.93+/-0.08; amyloid histology: 15.1%+/-1.

146 healthy male subjects each had two 120-min [11C]PBR28 PET scans in 1 d, before and after an LPS chal

147 This was in line with moderate 11C-PBB3 versus faint 18F-AV-1451 autoradiographic label

148 tudies in nonhuman primates with [11C]1e, N-[11C]guanyl-m-octopamine, which has a slow NET transport

149 g parameters for 11C-MMP under its new name, 11C-CUMI-101, in Papio anubis.

150 Four patients had normal 11C HED studies and four had mild denervation (global ex

151 MP acetylcholinesterase and caudate nucleus [11C]DTBZ monoaminergic positron-emission tomography imag

152 Therefore, we evaluated the ability of 11C-dLop to quantify the function of P-gp at the blood-b

153 Analysis of 11C-PBR28 PET data was not inconsistent with the existen

154 n of control and AD subjects on the basis of 11C-PIB uptake.

155 This study sought to quantify the binding of 11C-(R)-rolipram, a PDE4 inhibitor, as an indirect measu

156 nously) also blocked the specific binding of 11C-JHU75528 in the mouse and baboon brain, whereas vari

157 The specific binding of 11C-JHU75528 in vivo was blocked by preinjection of nonl

158 Increased binding of 11C-MeNTI and 11C-CFN was detected in all tumor types st

159 to improve the classification capability of 11C-PIB scans on patients with AD.

160 The concentration of 11C-dLop in the brain was low under baseline conditions

161 The brain concentrations of 11C-loperamide and the putative 11C-dLop were about 16-f

162 Should further demethylation of 11C-dLop occur, radiometabolites with low entry into the

163 in barrier, because further demethylation of 11C-dLop will generate radiometabolites that have little

164 blockade affected peripheral distribution of 11C-dLop, we measured whole-body biodistribution in 4 mo

165 still considerably higher than the doses of 11C-raclopride commonly used in research PET (370-555 MB

166 With the exception of 11C-PK11195, all TSPO PET ligands in current clinical ap

167 The single-pass extraction of 11C-dLop is high and requires correction for blood flow

168 starting immediately after the injection of 11C-methylaminoisobutyric acid (11C-MeAIB).

169 Subjects received single-bolus injections of 11C-raclopride (S-(-)-3,5-dichloro-N-[(1-ethyl-2-pyrroli

170 Levels of 11C-(R)-PK11195 binding potential were measured in a sel

171 major limitations are the short half-life of 11C and the rapid catabolism of thymidine after injectio

172 ysis was used to generate parametric maps of 11C-(R)-PK11195 binding potential.

173 s; 166.5 MBq +/- 43.0 (4.50 +/- 1.16 mCi) of 11C-CUMI-101 were injected as an intravenous bolus, and

174 Paired measurements of 11C-MeNTI and 11C-CFN binding were performed in biopsy-p

175 The major metabolites of 11C-choline were phosphocholine in HCC and betaine and c

176 he specific-to-nonspecific binding ratios of 11C-MeNTI and 11C-CFN, respectively.

177 Dynamic PET scans of 11C-choline were acquired using the woodchuck models of

178 ng carcinomas and suggest the suitability of 11C-MeNTI and 11C-CFN as investigational probes of lung

179 1.31; mean +/- SEM) was greater than that of 11C-CFN (2.42 +/- 1.17) but lower than that of 18F-FDG (

180 was significantly more intense than that of 11C-CFN.

181 ction for cerebral blood flow, the uptake of 11C-dLop was fairly uniform among brain regions, suggest

182 Asymmetry of [11C]DPA-713 was greater than that of [11C]PBR28 (F = 29.

183 tion did not affect the specific binding of [11C]cocaine in the striatum.

184 Binding of [11C]PBR28 was increased significantly in thalamus.

185 The specific binding of [11C]raclopride in the striatum and thalamus were signifi

186 pamine by comparing the specific binding of [11C]raclopride when subjects watched a neutral video (na

187 The binding potential (BPF) of [11C]WAY-100635 (calculated as the number of receptors av

188 Amphetamine-induced displacement of [11C]FLB 457 binding potential (DeltaBPND) was significan

189 After injection of [11C](-)-12a, there was high uptake and retention of radi

190 P < .001; r = -0.70; P < .001), but not of [11C]PiB binding.

191 cant difference in the binding potential of [11C]DASB between the recovered depressed patients and he

192 The binding properties of [11C]MeDAS for myelin were systematically evaluated by in

193 Polar radiometabolites of [11C](-)-12a appeared moderately slowly in plasma.

194 The influx rate of [11C]5-HTP as a measure of serotonin synthesis rate capac

195 olated rat hearts, neuronal uptake rates of [11C]1a-m ranged from 0.24 to 1.96 mL min-1 (g wet wt)-1,

196 odistribution and acute toxicity studies of [11C]MeDAS were also conducted.

197 son of standardized uptake values (SUVs) of [11C]DTBZ and blood glucose concentrations, loss of more

198 ry of [11C]DPA-713 was greater than that of [11C]PBR28 (F = 29.4; P = .001).

199 PET studies showed that the tumor uptake of [11C]14 in the NCI-H1975 xenografts was significantly hig

200 d brain beta-amyloidosis (A+ or A-) based on 11C-Pittsburgh compound B positron emission tomography.

201 nzothiazole (also known as 11C-6-OH-BTA-1 or 11C-PIB) binds to amyloid-beta (Abeta), which accumulate

202 in prostate cancer, namely 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.

203 ly 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.

204 ns between measures of brain AD pathology or 11C-PiB beta-amyloid load and glucose intolerance or ins

205 patially extended-when grey matter volume or 11C-PiB uptake maps were added as covariates.

206 [11C]-(+)-propyl-hexahydro-naphtho-oxazin ([11C]-(+)-PHNO).

207 [11C]Phenethylguanidine ([11C]1a) and 12 analogues ([11C]1b-m) were synthesized an

208 en 54 and 77 years underwent 11C-(R)PK11195, 11C-PIB positron emission tomography and magnetic resona

209 The in vivo imaging probe [11C]-PIB (Pittsburgh Compound B, N-methyl[11C]2-(4'-meth

210 ntrations of 11C-loperamide and the putative 11C-dLop were about 16-fold greater in P-gp knockout mic

211 Quantitative [11C]14-PET studies showed that the tumor uptake of [11C]

212 itron emission tomography with radiolabeled [11C]ABP688, which binds to an allosteric site with high

213 ng with the translocator protein radioligand 11C-PBR28 was performed at baseline.

214 Radioligand [11C](-)-12a is promising for the study of brain CB1 rece

215 e selective opioid receptor PET radioligand [11C]diprenorphine (DPN), quantified as a volume-of-distr

216 -loperamide and its putative radiometabolite 11C-dLop are avid P-gp substrates.

217 h the DA D2 receptor antagonist radiotracer [11C]raclopride detected significant activation of DA rel

218 itron emission tomography (PET) radiotracer [11C]PBR28, which binds to translocator protein, a molecu

219 micro-opioid receptor-selective radiotracer [11C]carfentanil after each 1-week inactive and active or

220 ed positron emission tomography radiotracer [11C]GSK931145 was used to quantify the relationship betw

221 y identifying and describing a radiotracer, [11C]GV1-57, that appears to specifically label olfactory

222 Here, we have evaluated a PET radiotracer, [11C]GV1-57, that specifically binds mature OSNs and quan

223 thyl-N-(2-pyridinyl)cyclohexaneca rboxamide [11C-WAY-100635], 4-(2'-methoxyphenyl)-1-[2'-(N-2''-pyrid

224 release during speech production and reduced 11C-raclopride binding to D2/D3 receptors at rest was se

225 with control subjects, patients had reduced 11C-raclopride binding to D2/D3 receptors at rest in the

226 tapping overlapped with a region of reduced 11C-raclopride binding to D2/D3 receptors at rest.

227 hted magnetic resonance imaging and relative 11C-PBR28 uptake in the normal-appearing white matter wa

228 Relative [11C]PBR28 and [11C]DPA-713 uptakes were higher ipsilater

229 was administered 180 min before the second [11C]PBR28 scan.

230 orophenyl)methylamide, termed [11C]SU11274 ([11C]14) for in vivo imaging of mesenchymal-epithelial tr

231 18F]AV-1451) (formerly known as [18F]T807), [11C]PiB PET, magnetic resonance imaging (MRI), neurologi

232 ic acid (3-chlorophenyl)methylamide, termed [11C]SU11274 ([11C]14) for in vivo imaging of mesenchymal

233 ron emission tomography (PET) probe, termed [11C]MeDAS, that is capable of longitudinally imaging cen

234 .2%+/-0.9%), and was lowest in the thalamus (11C-PIB BPND: 0.40+/-0.07; amyloid histology: 6.6%+/-0.6

235 se, with TSPO-binding PET ligands other than 11C-PBR28, for TSPO present in peripheral blood, and wit

236 All metabolites are more polar than 11C-CUMI-101, and no significant change in metabolites w

237 ased uptake after P-gp blockade suggest that 11C-dLop will be useful to measure a wide range of P-gp

238 in LPC and EAE rat models demonstrate that [11C]MeDAS uptake changes correlate with associated myeli

239 These studies demonstrated that [11C]14-PET is an appropriate imaging marker for quantifi

240 This study demonstrates that [11C]CUMI-101 is a selective 5-HT1AR ligand for in vivo a

241 Our results suggest that [11C]DASB parametric imaging of BP and R1 with the noninv

242 The 11C-PIB PET data were quantified to nondisplaceable bind

243 le image, was calculated on the basis of the 11C-MeAIB images.

244 inoid drugs did not significantly reduce the 11C-JHU75528 binding in the mouse brain.

245 The [11C]-(+)-PHNO binding ratio in D3-rich SN versus D2-rich

246 The [11C]methylreboxetine-binding potential of NET availabili

247 The [11C]PBR28 distribution volume (VT) corrected for free fr

248 The [11C]PBR28 VT to fp ratio was higher in patients with TLE

249 We quantified the [11C]PiB distribution volume ratio and standardized uptak

250 teral to seizure foci in patients with TLE ([11C]PBR28: 2%-6%; [11C]DPA-713: 4%-9%).

251 ein (P-gp), but it is rapidly metabolized to 11C-N-desmethyl-loperamide (11C-dLop), which is also a s

252 11C-dLop may be superior to 11C-loperamide in measuring P-gp function at the blood-b

253 resection.Increased uptake of the PET tracer 11C-alpha-methyl tryptophan shows promise for localizing

254 rols) aged between 54 and 77 years underwent 11C-(R)PK11195, 11C-PIB positron emission tomography and

255 mean [SD] age, 34.7 [9.2] years) underwent [11C]5-HTP PET imaging.

256 ity of 5-HT1A agents currently in human use (11C-labeled N-(2-[4-(2-methoxyphenyl)-1-piperazinyl]ethy

257 Using 11C-(R)-PK11195 (PK) positron emission tomography (PET),

258 The agreement using 11C-MeAIB, parametric imaging, and fixed thresholding of

259 Our dual-modality imaging approach using 11C-PIB PET/7 T MR imaging and 16.4 T microscopic MR ima

260 esonance imaging and were dichotomized using 11C-labelled Pittsburgh compound B positron emission tom

261 sms in LIDs development in PD patients using 11C-DASB PET to evaluate serotonin terminal function and

262 y amyloid positron emission tomography using 11C-Pittsburgh B compound (PiB-PET).

263 Using [11C]DPA-713 positron emission tomographic data from 12 a

264 Furthermore, using [11C]MeDAS-PET, the efficacy of myelin repair therapy wit

265 asured the binding potential of 5-HTT using [11C]DASB in conjunction with positron emission tomograph

266 eled with carbon-11 (t1/2 ) 20.4 min) using [11C]cyanide ion as labeling agent and evaluated as PET r

267 cortical Abeta deposition, quantified using [11C] Pittsburgh-compound-B (PIB)-PET.

268 raphy-based regional measures of TSPO using [11C]DPA-713, diffusion tensor imaging measures of region

269 cose metabolism in three PPA variants using [11C]-Pittsburgh compound B ([11C]PIB) and [18F]-labeled

270 rther control for local grey matter volumes, 11C-PiB uptake, or both.

271 erived U87MG tumor volumes was achieved with 11C-MeAIB, MAP3D reconstruction, and fixed thresholding

272 Imaging with 11C-thymidine has been tested for detecting tumors and t

273 Monkeys were injected with 11C-loperamide, and PET brain images were acquired for 1

274 striatal neuronal dysfunction measured with 11C-raclopride (RAC) PET, and the role of PK PET as a po

275 were 122.1 mm3 using 18F-FDG, 118.3 mm3 with 11C-MeAIB, and 125.4 mm3 by histology.

276 was 35.0 mm3 using 18F-FDG and 34.1 mm3 with 11C-MeAIB, compared with 33.7 mm3 by histology.

277 Cardiac PET was performed with 11C HED in 27 patients with IPD (20 men and seven women

278 Using PET with 11C-acetate, 18FDG, and 18F-fluoro-thiaheptadecanoic aci

279 PET with 11C-choline showed an HCC detection rate of 9 of 10.

280 nd choline tracer uptake in HCC for PET with 11C-choline.

281 PET with 11C-dLop can quantify P-gp function at the blood-brain b

282 labelling of Alzheimer's disease slices with 11C-PBB3 and 18F-AV-1451 were noted.

283 sured with positron emission tomography with 11C altropane.

284 h human brain PET data acquired in vivo with 11C-PBR28.

285 Similar to prior work with 11C-thymidine, identifiability analysis showed that K1 (

286 to measure brain microglial activation with [11C]PBR28 PET provides an approach to test new medicatio

287 contribution of 5-HT1A autoreceptors (with [11C]WAY100635 positron emission tomography) to amygdala

288 he association of [18F]AV-1451 binding with [11C]PiB binding, and the association of [18F]AV-1451 bin

289 PET imaging with [11C] dihydrotetrabenazine, insulin staining, and microva

290 individuals underwent amyloid imaging with [11C]PiB PET.

291 subjects were followed longitudinally with [11C]-raclopride and [18F]-fluorodeoxyglucose PET imaging

292 cose) and dopamine increases (measured with [11C]raclopride, a D2/D3 receptor ligand with binding tha

293 and seven mother-reared rhesus monkeys with [11C]DASB positron emission tomography (PET) imaging.

294 ing positron emission tomography (PET) with [11C]-WAY-100635 before and after treatment of MDD with a

295 phy (PET) studies in nonhuman primates with [11C]1e, N-[11C]guanyl-m-octopamine, which has a slow NET

296 point, the subjects were also scanned with [11C]-raclopride PET and structural MRI to measure concur

297 8 patients and 7 controls were scanned with [11C]DPA-713.

298 d 11 age-matched controls were scanned with [11C]PBR28, and 8 patients and 7 controls were scanned wi

299 by PET imaging of the transplant site with [11C] dihydrotetrabenazine.

300 yl))-N-(2-pyridyl)-cyclohexanecarbo xamide ([11C]WAY-100635), a serotonin1A antagonist; a subset of 5